Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 243 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer Clear all

Conditions: Influenza
Interventions: CAIV-T or TIV; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 2
States / cities: New Port Richey, Florida • Charlottesville, Virginia

Conditions: Liver Cirrhosis, Biliary
Interventions: tigecycline; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Saint Paul, Minnesota • Durham, North Carolina

Conditions: Osteoarthritis
Interventions: AGG-523; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 3
States / cities: Anaheim, California • Miami, Florida • Altoona, Pennsylvania

Conditions: COPD
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 45 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Healthy
Interventions: levonorgestrel/ethinyl estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Neoplasms
Interventions: MST-997; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: New York, New York • Cleveland, Ohio • Nashville, Tennessee

Conditions: Menstruation Disturbances, Premenstrual Syndrome
Interventions: levonorgestrel/ethinyl estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 69
States / cities: Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more

Conditions: Major Depressive Disorder
Interventions: Desvenlafaxine Succinate Sustained-Release 10mg, Desvenlafaxine Succinate Sustained-Release 50 mg, placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Encino, California • Newport Beach, California + 21 more

Conditions: Fibroid
Interventions: PRA-027; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Fibromyalgia
Interventions: Desvenlafaxine Sustained Release; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 59
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more

Conditions: Advanced Solid Tumors
Interventions: Temsirolimus and capecitabine; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Brain Neoplasms
Interventions: Temsirolimus (Torisel); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sarcoma
Interventions: temsirolimus plus liposomal doxorubicin; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 1 Year and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Psoriasis
Interventions: ILV-094; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Beverly Hills, California • Santa Monica, California • South Miami, Florida + 9 more

Conditions: Graft Rejection, Kidney Failure
Interventions: cyclosporine or tacrolimus, sirolimus; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 8
States / cities: Tampa, Florida • Rochester, Minnesota • New York, New York + 4 more

Conditions: Diabetic Neuropathies, Pain
Interventions: DVS SR, Placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 51
States / cities: Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 47 more

Conditions: Alzheimer's Disease
Interventions: SRA-333; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 3
States / cities: Phoenix, Arizona • Fort Lauderdale, Florida • Miami, Florida

Conditions: Advance Illness Patients With OIC
Interventions: SC Methylnaltrexone, SC Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Postmenopause
Interventions: Bazedoxifene/conjugated estrogens; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Gastroesophageal Reflux
Interventions: pantoprazole for approximately 9 weeks.; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 23
States / cities: Little Rock, Arkansas • Orange, California • San Diego, California + 19 more

Conditions: Uterine Leiomyomata (Fibroids)
Interventions: PRA-027; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Beverly Hills, California • Miami, Florida

Conditions: Gastroesophageal Reflux
Interventions: pantoprazole; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 28 Weeks to 11 Months
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Schizophrenia
Interventions: NSA-789 at 2 different doses; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: HIV Infections
Interventions: HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine), Sodium chloride injection USP (0.9%); Biological
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 6
States / cities: Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more

Search by objective public record fields.

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older

Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

Study Evaluating AGG-523 in Subjects With Osteoarthritis

Evaluation of Airway Gene Expression in COPD and Controlled Populations

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential

Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome

A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer

Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

Study of Methylnaltrexone (MNTX) for the Relief of Constipation

Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms

Study Evaluating Pantoprazole in Children With GERD

Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women

Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants

Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients

Study Evaluating Vaccine in Adults With HIV